Photodynamic Diagnosis in Urology: State-of-the-Art

Filbeck, 2002, Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma?, Urology, 60, 1025, 10.1016/S0090-4295(02)01961-1 Frimberger, 2001, Autofluorescence imaging to optimize 5-ALA-induced fluorescence endoscopy of bladder carcinoma, Urology, 58, 372, 10.1016/S0090-4295(01)01222-5 Herth, 2003, Autofluorescence bronchoscopy—a comparison of two systems (LIFE and D-Light), Respiration, 70, 395, 10.1159/000072903 Frimberger, 2002, Autofluorescence and 5-aminolevulinic acid induced fluorescence diagnosis of penile carcinoma—new techniques to monitor Nd:YAG laser therapy, Urol Res, 30, 295, 10.1007/s00240-002-0255-4 Pinthus, 2006, Photodynamic therapy for urological malignancies: past to current approaches, J Urol, 175, 1201, 10.1016/S0022-5347(05)00701-9 Whitmore, 1964, Tetracycline ultraviolet fluorescence in bladder carcinoma, Cancer, 17, 1528, 10.1002/1097-0142(196412)17:12<1528::AID-CNCR2820171203>3.0.CO;2-# Baumgartner, 1987, A fluorescence imaging device for endoscopic detection of early stage cancer—instrumental and experimental studies, Photochem Photobiol, 46, 759, 10.1111/j.1751-1097.1987.tb04844.x Saarnak, 1998, Influence of tumour depth, blood absorption and autofluorescence on measurements of exogenous fluorophores in tissue, Lasers Med Sci, 13, 22, 10.1007/BF00592957 Stepp, 1997, New developments in fluorescence detection of ALA-induced Protoporphyrin IX for cancer localization, SPIE Proc, 3197, 68, 10.1117/12.297952 Batlle, 1993, Porphyrins, porphyrias, cancer and photodynamic therapy—a model for carcinogenesis, J Photochem Photobiol B, 20, 5, 10.1016/1011-1344(93)80127-U Fukuda, 2005, Aminolevulinic acid: from its unique biological function to its star role in photodynamic therapy, Int J Biochem Cell Biol, 37, 272, 10.1016/j.biocel.2004.04.018 Greenbaum, 2003, A porphobilinogen deaminase (PBGD) Ran-binding protein interaction is implicated in nuclear trafficking of PBGD in differentiating glioma cells, Oncogene, 22, 5221, 10.1038/sj.onc.1206723 2006 Fotinos, 2006, 5-Aminolevulinic acid derivatives in photomedicine: characteristics, application and perspectives, Photochem Photobiol, 82, 994, 10.1562/2006-02-03-IR-794 Doring, 1998, Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications, J Clin Invest, 101, 2761, 10.1172/JCI1909 Skalkos, 2006, Photophysical properties of Hypericum perforatum L. extracts—novel photosensitizers for PDT, J Photochem Photobiol B, 82, 14651, 10.1016/j.jphotobiol.2005.11.001 Stavropoulos, 2006, Hypericum perforatum L. extract—novel photosensitizer against human bladder cancer cells, J Photochem Photobiol B, 84, 649, 10.1016/j.jphotobiol.2006.02.001 Saw, 2006, Spectroscopic characterization and photobleaching kinetics of hypericin-N-methyl pyrrolidone formulations, Photochem Photobiol Sci, 5, 101823, 10.1039/b602807a Rall, 1957, Appearance and persistence of fluorescent material in tumor tissue after tetracycline administration, J Natl Cancer Inst, 19, 79 Kelly, 1975, Haematoporphyrins in the diagnosis and treatment of carcinoma of the bladder, Proc R Soc Med, 68, 527 Jocham, 1985, Integral photodynamic therapy of multifocal bladder cancer Initial clinical experiences, Urologe A, 24, 316 Nseyo, 1985, Whole bladder photodynamic therapy for transitional cell carcinoma of bladder, Urology, 26, 274, 10.1016/0090-4295(85)90125-6 Dougherty, 1986, Photosensitization of malignant tumors, Semin Surg Oncol, 24, 10.1002/ssu.2980020104 Baert, 1993, Clinical fluorescence diagnosis of human bladder carcinoma following low-dose Photofrin injection, Urology, 41, 322, 10.1016/0090-4295(93)90588-2 Baumgartner, 1991, First clinical experiences with photodynamic fluorescence diagnosis in urology, 107 Kennedy, 1990, Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience, J Photochem Photobiol B, 6, 143, 10.1016/1011-1344(90)85083-9 Kriegmair, 1992, Intravesikuläre Instillation von Delta-Aminolävulinsäure (ALA)—Eine neue Methode zur photodynamischen Diagnostik und Therapie, Laser-Medizin, 8, 83 Tritschler, 2007, Validation of the diagnostic value of NMP22® BladderChek® test as a marker for bladder cancer by photodynamic diagnosis, Eur Urol, 51, 403, 10.1016/j.eururo.2006.08.001 Alken P, Siegsmund M, Gromoll-Bergmann K, Daffner P, Fenner W, Spelz J. A randomized controlled multicentre trial to compare the effects of transurethral resection of bladder carcinomas under 5-ALA induced fluorescence light to conventional white light. Poster presented at the annual EAU Congress, 21–24 March 2007, Berlin, Germany. Fradet, 2007, A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study, J Urol, 178, 68, 10.1016/j.juro.2007.03.028 Jichlinski, 2003, Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer—a multicenter study, J Urol, 170, 226, 10.1097/01.ju.0000060782.52358.04 Jocham, 2005, Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study, J Urol, 174, 862, 10.1097/01.ju.0000169257.19841.2a Schmidbauer, 2004, Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy, J Urol, 171, 135, 10.1097/01.ju.0000100480.70769.0e Filbeck, 2002, Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors, J Urol, 168, 67, 10.1016/S0022-5347(05)64833-1 Kriegmair, 2002, Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy, J Urol, 168, 475, 10.1016/S0022-5347(05)64661-7 Riedl, 2001, Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer, J Urol, 165, 1121, 10.1016/S0022-5347(05)66442-7 Denzinger, 2007, Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study, Urology, 69, 675, 10.1016/j.urology.2006.12.023 Babjuk, 2005, 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer, BJU Int, 96, 798, 10.1111/j.1464-410X.2004.05715.x Daniltchenko, 2005, Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study, J Urol, 174, 2129, 10.1097/01.ju.0000181814.73466.14 Penkoff H, Steiner H, Dajc-Sommerer E, et al. Transurethral detection and resection of bladder carcinomas under white or 5-ALA induced fluorescence light: results of the first double-blind placebo-controlled clinical trial. Abstract no. 1085 presented at the annual American Urological Association congress, May 19–24, 2007, Anaheim, CA. Filbeck, 1999, 5-Aminolevulinic acid-induced fluorescence endoscopy applied at secondary transurethral resection after conventional resection of primary superficial bladder tumors, Urology, 53, 77, 10.1016/S0090-4295(98)00430-0 Grimbergen, 2003, Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy, Eur Urol, 44, 51, 10.1016/S0302-2838(03)00210-0 Hendricksen, 2006, False-positive lesions detected by fluorescence cystoscopy: any association with p53 and p16 expression?, World J Urol, 24, 597, 10.1007/s00345-006-0109-8 Obermann, 2003, Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses, J Pathol, 199, 50, 10.1002/path.1259 Loidl, 2005, Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance?, Eur Urol, 47, 323, 10.1016/j.eururo.2004.10.025 Witjes, 2005, Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective phase II study, Eur Urol, 47, 319, 10.1016/j.eururo.2004.09.017 Marti, 2003, Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer, J Urol, 170, 428, 10.1097/01.ju.0000075054.38441.2d D’Hallewin, 2000, Fluorescence detection of flat bladder carcinoma in situ after intravesical instillation of hypericin, J Urol, 164, 349, 10.1016/S0022-5347(05)67357-0 D’Hallewin, 2002, Hypericin-based fluorescence diagnosis of bladder carcinoma, BJU Int, 89, 760, 10.1046/j.1464-410X.2002.02690.x Sim, 2005, Is photodynamic diagnosis using hypericin better than white-light cystoscopy for detecting superficial bladder carcinoma?, BJU Int, 95, 1215, 10.1111/j.1464-410X.2005.05508.x van der Meijden, 2005, EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ, Eur Urol, 48, 363, 10.1016/j.eururo.2005.05.011 Koenig, 1999, Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced by 5-aminolaevulinic acid, BJU Int, 83, 129, 10.1046/j.1464-410x.1999.00917.x Kamuhabwa, 2005, Determination of hypericin in human plasma by high-performance liquid chromatography after intravesical administration in patients with transitional cell carcinoma of the bladder, Eur J Pharm Biopharm, 59, 469, 10.1016/j.ejpb.2004.09.013 Klem, 2006, Determination of the bioavailability of [14C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers, J Clin Pharmacol, 46, 456, 10.1177/0091270006286849 Rick, 1997, Pharmacokinetics of 5-aminolevulinic acid-induced protoporphyrin IX in skin and blood, J Photochem Photobiol B, 40, 313, 10.1016/S1011-1344(97)00076-6 Colapaoli, 2006, A case of anaphylactic shock possibly caused by intravesical Hexvix, Acta Anaesthesiol Scand, 50, 1165, 10.1111/j.1399-6576.2006.01110.x Tauber, 2006, Integral spectrophotometric analysis of 5-aminolaevulinic acid-induced fluorescence cytology of the urinary bladder, BJU Int, 97, 992, 10.1111/j.1464-410X.2006.06094.x Cunderlikova, 2007, Detection of urinary bladder cancer with flow cytometry and hexaminolevulinate in urine samples, Cytopathology, 18, 87, 10.1111/j.1365-2303.2007.00436.x Pytel, 2002, New aspect of photodynamic diagnosis of bladder tumors: fluorescence cytology, Urology, 59, 216, 10.1016/S0090-4295(01)01528-X Schneede, 2001, Fluorescence urethroscopy following instillation of 5-aminolevulinic acid: a new procedure for detecting clinical and subclinical HPV lesions of the urethra, J Eur Acad Dermatol Venereol, 15, 121, 10.1046/j.1468-3083.2001.00249.x Fehr, 1996, Selective photosensitizer distribution in vulvar condyloma acuminatum after topical application of 5-aminolevulinic acid, Am J Obstet Gynecol, 174, 951, 10.1016/S0002-9378(96)70332-0 Ross, 1997, Selectivity of protoporphyrin IX fluorescence for condylomata after topical application of 5-aminolaevulinic acid: implications for photodynamic treatment, Br J Dermatol, 137, 736, 10.1111/j.1365-2133.1997.tb01110.x Zaak, 2003, Recurrence of condylomata acuminata of the urethra after conventional and fluorescence-controlled Nd:YAG laser treatment, Urology, 61, 1011, 10.1016/S0090-4295(02)02527-X Frimberger, 2004, Fluorescence diagnosis: a novel method to guide radical inguinal lymph node dissection in penile cancer, World J Urol, 22, 150, 10.1007/s00345-003-0352-1 Popken, 1999, Kidney-preserving tumour resection in renal cell carcinoma with photodynamic detection by 5-aminolaevulinic acid: preclinical and preliminary clinical results, BJU Int, 83, 578, 10.1046/j.1464-410x.1999.00977.x Zaak, 2003, Photodynamic therapy by means of 5-ALA induced PPIX in human prostate cancer—preliminary results, Med Laser Appl, 18, 91, 10.1078/1615-1615-00092 Zaak, 2001, Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection, J Urol, 166, 1665, 10.1016/S0022-5347(05)65649-2 Baeumler, 2003, Fluorescence diagnosis and photodynamic therapy in dermatology, Med Laser Appl, 18, 47, 10.1078/1615-1615-00087 Witjes, 2006, Management of BCG failures in superficial bladder cancer: a review, Eur Urol, 49, 790, 10.1016/j.eururo.2006.01.017 Brausi, 2002, Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies, Eur Urol, 41, 523, 10.1016/S0302-2838(02)00068-4 Parmar, 1989, Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party), J Urol, 142, 284, 10.1016/S0022-5347(17)38731-1 Kurth, 1995, Factors affecting recurrence and progression in superficial bladder tumours, Eur J Cancer, 31A, 1840, 10.1016/0959-8049(95)00287-S Kriegmair, 1996, Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence, J Urol, 155, 105, 10.1016/S0022-5347(01)66559-5 Riedl, 1999, Fluorescence detection of bladder tumors with 5-amino-levulinic acid, J Endourol, 13, 755, 10.1089/end.1999.13.755 Filbeck, 1999, Clinical results of the transurethral resection and evaluation of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid, J Endourol, 13, 117, 10.1089/end.1999.13.117 Zaak, 2002, Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions, Cancer, 95, 1234, 10.1002/cncr.10821 Hungerhuber, 2007, Seven years’ experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder, Urology, 69, 260, 10.1016/j.urology.2006.10.015 Jichlinski, 2003, New diagnostic strategies in the detection and staging of bladder cancer, Curr Opin Urol, 13, 351, 10.1097/00042307-200309000-00001 D’Hallewin, 2002, Fluorescence detection of bladder cancer: a review, Eur Urol, 42, 417, 10.1016/S0302-2838(02)00402-5